RE-BVS – Piemonte Repository

Sfoglia per AUTORE
BIGHIN C
Collezione ASL Città di Torino

Items : 4

SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2023 Dec 15;29(24):5217-5226. doi: 10.1158/1078-0432.CCR-23-1568.

2023
ASL Città di Torino
AOU Città della Salute di Torino

Cardinali B; Prat A; Brasó-Maristany F; Rossi M; Scognamiglio G; Generali D; Fabi A; Porpiglia M; Frassoldati A; Puglisi F; Mansutti M; Turletti A; De Angioletti M; Lunardi G; Notaro R; Montemurro F; Ponzone R; Pazzola A; Schettini F; De Placido S; Tamberi S; Garrone O; Gori S; Sanna G; Durando A; Boni L; Bisagni G; Conte B; Piccioli P; et alii...

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2022 Dec;23(12):1571-1582. doi: 10.1016/S1470-2045(22)00632-5. Epub 2022 Nov 10.

2022
ASL Città di Torino

Del Mastro L; Poggio F; Blondeaux E; De Placido S; Giuliano M; Forestieri V; De Laurentiis M; Gravina A; Bisagni G; Rimanti A; Turletti A; Nisticò C; Vaccaro A; Cognetti F; Fabi A; Gasparro S; Garrone O; Alicicco MG; Urracci Y; Mansutti M; Poletti P; Correale P; Bighin C; Puglisi F; Montemurro F; Colantuoni G; Lambertini M; Boni L;

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. in NPJ breast cancer / NPJ Breast Cancer. 2021 Jun 28;7(1):82. doi: 10.1038/s41523-021-00286-w.

2021
ASL Città di Torino
AOU Città della Salute di Torino

Gamucci T; Colantuoni G; Garrone O; Ardizzoni A; Turletti A; Durando A; Bisagni G; Giuliano M; De Laurentiis M; Bighin C; Russo S; Montemurro F; Boni L; Ceppi M; Lambertini M; Gerratana L; Puglisi F; Gravina A; De Placido S; Cognetti F; Del Mastro L;

Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. in International journal of cancer / Int J Cancer. 2020 Jul 1;147(1):160-169. doi: 10.1002/ijc.32789. Epub 2019 Dec 4.

2020
ASL Città di Torino

Lambertini M; Poggio F; Bruzzone M; Conte B; Bighin C; de Azambuja E; Giuliano M; De Laurentiis M; Cognetti F; Fabi A; Bisagni G; Durando A; Turletti A; Urracci Y; Garrone O; Puglisi F; Montemurro F; Ceppi M; Del Mastro L;